Biodesix Competitors

Biodesix (NASDAQ:BDSX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Biodesix and Heron Therapeutics' revenue, earnings per share and valuation.

Biodesix has higher earnings, but lower revenue than Heron Therapeutics.

Institutional & Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Biodesix and Heron Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biodesix and Heron Therapeutics, as reported by MarketBeat.com.

Biodesix presently has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Heron Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 48.06%. Given Biodesix's stronger consensus rating and higher possible upside, research analysts plainly believe Biodesix is more favorable than Heron Therapeutics.

Summary

Biodesix beats Heron Therapeutics on 5 of the 8 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Biodesix and Amneal Pharmaceuticals' revenue, earnings per share and valuation.

Biodesix has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Institutional & Insider Ownership

33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 26.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Biodesix and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biodesix and Amneal Pharmaceuticals, as reported by MarketBeat.com.

Biodesix presently has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Amneal Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 31.83%. Given Biodesix's stronger consensus rating and higher possible upside, research analysts plainly believe Biodesix is more favorable than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Biodesix on 7 of the 9 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Biodesix and Replimune Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Biodesix and Replimune Group, as reported by MarketBeat.

Biodesix presently has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Replimune Group has a consensus price target of $56.00, suggesting a potential upside of 64.75%. Given Biodesix's higher possible upside, equities analysts clearly believe Biodesix is more favorable than Replimune Group.

Earnings and Valuation

This table compares Biodesix and Replimune Group's top-line revenue, earnings per share (EPS) and valuation.

Insider and Institutional Ownership

55.8% of Replimune Group shares are held by institutional investors. 50.9% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PMV Pharmaceuticals (NASDAQ:PMVP) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for PMV Pharmaceuticals and Biodesix, as provided by MarketBeat.com.

PMV Pharmaceuticals presently has a consensus target price of $38.00, suggesting a potential upside of 9.10%. Biodesix has a consensus target price of $26.00, suggesting a potential upside of 73.22%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than PMV Pharmaceuticals.

Earnings & Valuation

This table compares PMV Pharmaceuticals and Biodesix's top-line revenue, earnings per share and valuation.

Profitability

This table compares PMV Pharmaceuticals and Biodesix's net margins, return on equity and return on assets.

Institutional and Insider Ownership

69.7% of PMV Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biodesix beats PMV Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Profitability

This table compares Supernus Pharmaceuticals and Biodesix's net margins, return on equity and return on assets.

Institutional and Insider Ownership

96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Supernus Pharmaceuticals and Biodesix, as reported by MarketBeat.

Supernus Pharmaceuticals presently has a consensus price target of $37.50, suggesting a potential upside of 27.77%. Biodesix has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Given Biodesix's higher probable upside, analysts clearly believe Biodesix is more favorable than Supernus Pharmaceuticals.

Earnings and Valuation

This table compares Supernus Pharmaceuticals and Biodesix's gross revenue, earnings per share (EPS) and valuation.

Supernus Pharmaceuticals has higher revenue and earnings than Biodesix.

Summary

Supernus Pharmaceuticals beats Biodesix on 6 of the 8 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares ADC Therapeutics and Biodesix's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ADC Therapeutics and Biodesix, as reported by MarketBeat.

ADC Therapeutics currently has a consensus price target of $49.25, suggesting a potential upside of 119.08%. Biodesix has a consensus price target of $26.00, suggesting a potential upside of 73.22%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Biodesix.

Institutional and Insider Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADC Therapeutics and Biodesix's revenue, earnings per share and valuation.

Biodesix has lower revenue, but higher earnings than ADC Therapeutics.

Summary

ADC Therapeutics beats Biodesix on 3 of the 4 factors compared between the two stocks.